<DOC>
	<DOCNO>NCT02328950</DOCNO>
	<brief_summary>A 5 day course fludarabine cytarabine ( FA ) administer follow full intensity condition regimen ( Bucy ) set allogeneic stem cell transplantation ( SCT ) . The purpose study explore antileukemic , immunosuppressive effect safety FA backbone condition regiment treatment patient high-risk , recurrent refractory acute Leukemia advance myelodysplastic syndrome .</brief_summary>
	<brief_title>A 5 Day Course Fludarabine Cytarabine Followed Full Intensity Allogeneic Stem Cell Transplantation ( FA5-Bucy ) Treating Patients With High-risk , Recurrent Refractory Acute Leukemia Advanced Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Signed write informed consent Aged 065 year Patients suffer either refractory de novo AML/ALL relapse AML/ALL patient high risk AML/ALL CR1 Patients advance MDS Cardiac : Left ventricular ejection fraction ≥ 50 % Adequate renal hepatic function Performance status : Karnofsky ≥ 70 % Pregnant lactating female Current participation another clinical trial Contraindication one drug regimen Any severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver organ system may place patient undue risk undergo agent include condition regimen</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>